title: Management of metastatic melanoma patients with brain metastases.
abstract: Brain metastases seem to be an almost inevitable complication in patients with metastatic melanoma. Except for the rare patients who can undergo successful surgical resection of brain metastases, current management strategies do not appear adequate and result in a poor outcome (median survival, 2-4 months). In recent small series, stereotactic radiosurgery or gamma-knife treatment has suggested improvement in local control compared with whole brain radiation therapy. We have recently shown prolonged survival (11.1 months) using a multimodality treatment approach in 44 sequential patients with melanoma brain metastases. A subsequent study demonstrated that the outcome of biochemotherapy for metastatic melanoma is not affected by the presence or absence of brain metastases. Our results suggest that the outcome of patients with melanoma brain metastases can be improved using a multidisciplinary management strategy.
authors: Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, One Breakthrough Way, 10441 W. Twain Avenue, Las Vegas, NV 89135, USA.
authors: Martin
authors: M
authors: Majer
authors: Wolfram E
authors: WE
authors: Samlowski
mesh_terms: D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D016634:Radiosurgery / Q000379:methods; D012878:Skin Neoplasms / Q000473:pathology*; D015996:Survival Rate
references: J Neurosurg. 2000 Jul;93(1):9-18
references: 10883899
references: CNS Drugs. 2002;16(5):325-38
references: 11994022
references: J Clin Oncol. 2004 Apr 1;22(7):1293-300
references: 15051777
references: Strahlenther Onkol. 1998 May;174(5):275-8
references: 9614957
references: Med Oncol. 2000 Nov;17(4):279-86
references: 11114706
references: J Exp Clin Cancer Res. 2000 Mar;19(1):21-34
references: 10840932
references: Melanoma Res. 2002 Apr;12 (2):175-8
references: 11930115
references: Cancer Invest. 2004;22(4):492-7
references: 15565805
references: Neurosurgery. 1999 Jan;44(1):59-64; discussion 64-6
references: 9894964
references: J Cancer Res Clin Oncol. 2002 Apr;128(4):214-8
references: 11935312
references: J Neurosurg. 2002 Dec;97(5 Suppl):494-8
references: 12507084
references: Ann Surg Oncol. 1995 Sep;2(5):392-9
references: 7496833
references: J Clin Oncol. 2002 Sep 1;20(17 ):3644-50
references: 12202665
references: Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1097-106
references: 15234044
references: Onkologie. 2004 Apr;27(2):145-9
references: 15138346
references: Curr Probl Cancer. 1999 Mar-Apr;23(2):59-98
references: 10333375
references: Cancer. 1990 Nov 15;66(10):2105-10
references: 2224765
references: Lancet. 2004 May 22;363(9422):1665-72
references: 15158627
references: J Neurosurg. 1998 Jan;88(1):11-20
references: 9420067
references: Cancer. 2007 May 1;109(9):1855-62
references: 17351953
references: J Clin Oncol. 2004 Jun 1;22(11):2101-7
references: 15169796
references: J Neurooncol. 2005 Feb;71(3):307-13
references: 15735922
references: Neurosurgery. 2004 Nov;55(5):1076-85
references: 15509314
references: Curr Opin Oncol. 2004 Jul;16(4):309-13
references: 15187883
references: Neurology. 1990 Jan;40(1):158-60
references: 2296364
references: Oncology (Williston Park). 1999 Jul;13(7):941-54, 957-61; discussion 961-2, 9
references: 10442342
references: J Neurosurg. 2005 Jan;102 Suppl:287-8
references: 15662827
references: Neurol Res. 1987 Jun;9(2):60-8
references: 2886946
references: Cancer. 2007 Sep 15;110(6):1329-37
references: 17623835
references: J Neurosurg. 2002 Mar;96(3):544-51
references: 11883840
references: J Clin Oncol. 2005 Dec 1;23(34):8870-6
references: 16314647
references: Oncogene. 2004 Jan 8;23(1):1-8
references: 14712205
references: Radiother Oncol. 2004 Jun;71(3):259-65
references: 15172140
references: Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):581-9
references: 9806518
references: Cancer. 1981 Mar 15;47(6):1262-6
references: 6164470
references: Eur J Cancer. 1998 Jul;34(8):1187-92
references: 9849477
references: Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):41-4
references: 6767663
references: Acta Chir Scand. 1951 Dec 13;102(4):316-9
references: 14914373
references: Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
references: 10098435
references: Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
references: 9128946
references: J Clin Oncol. 2000 Jan;18(1):158-66
references: 10623706
references: Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):809-16
references: 16682138
references: Stereotact Funct Neurosurg. 2002;79(3-4):245-55
references: 12890983
references: Cancer. 1996 Oct 1;78(7):1470-6
references: 8839553
references: Ann Neurol. 1993 Jun;33(6):583-90
references: 8498838
references: Expert Rev Neurother. 2004 Jul;4(4):673-9
references: 15853586
references: Strahlenther Onkol. 2003 Jun;179(6):366-71
references: 12789461
references: Am J Clin Oncol. 2003 Aug;26(4):354-7
references: 12902884
references: Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1837-9
references: 4044346
references: Semin Oncol. 2002 Oct;29(5):427-45
references: 12407508
references: Ann Surg Oncol. 1996 Mar;3(2):118-23
references: 8646510
references: Cancer. 2004 Aug 15;101(4):825-33
references: 15305416
references: Int J Radiat Oncol Biol Phys. 1982 Jul;8(7):1131-4
references: 7118615
references: Curr Treat Options Oncol. 2005 May;6(3):185-93
references: 15869730
references: N Engl J Med. 1990 Feb 22;322(8):494-500
references: 2405271
references: Br J Radiol. 1982 Aug;55(656):605-7
references: 6180791